Replies to post #627623 on NorthWest Biotherapeutics Inc (NWBO)

[The Danish Dude]

OS is the gold standard and FDA mandated crossover.

The amnesia biasheimers stricken shorts continue their death rattle bullshitting.

[improving]

Not your best work:
OS is not the "gold standard" it was the only option left to nwbo

"Clinical endpoints in oncology - a primer"
Amanda Delgado and Achuta Kumar Guddati

"Since the goal of cancer treatment is generally to extend survival, OS is often referred to as the gold standard endpoint in oncology clinical trials [6]."

[Roman516]

OS is the "Gold Standard" that is a fact.
Get off the past and focus on the present. NWBO issues with PFS where surpassed by the true
OS results.

PFS and OS basics 101
“Progression-Free Survival (PFS)
Another important endpoint for measuring the effectiveness of cancer drugs is progression-free survival, or PFS – how long a person lives without the disease worsening. PFS results are typically available earlier in a trial than OS data. PFS is considered an indication of disease control and stabilization.
Progressive-Free (PFS)
Measures how long patients live without the disease growing or spreading in the
treatment group compared to a control group.

Overall Survival (OS)
Overall survival, or OS, measures how long patients, who undergo a certain treatment regimen, live compared to patients who are in a control group (i.e., taking either another drug or an inactive treatment, known as a placebo). If a clinical trial demonstrates improved OS, it provides evidence of the drug’s value in prolonging a cancer patient’s life. OS is a strong and precise endpoint, as it requires having more patients and longer follow-ups compared to other clinical trial endpoints. Given all this, OS is often considered the “gold standard” for measuring the clinical benefits of a cancer drug.
Overall Survival (OS)
• Measures how long patients in the treatment group live compared to a controlled group.
• Is known as the gold standard in oncology clinical trials. “
Source
https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2018/clinical-trial-endpoints-in-cancer-research-four-terms-you-should-know-09242018.html#

[dennisdave]

Your explanation is correct other than "OS is not the "gold standard""

Overall survival (OS) is the gold standard to assess novel therapeutics to treat cancer. However, to identify early efficacy and speed up drug approval, trials have used progression-free survival (PFS) as a surrogate endpoint (SE). Herein, we aimed to examine if PFS could function as an OS surrogate in advanced Esophageal Squamous Cell Carcinoma (ESCC) treated with first-line immunochemotherapy.

https://bmccancer.biomedcentral.com/articles/10.1186/s12885-023-10613-y#:~:text=Overall%20survival%20(OS)%20is%20the,a%20surrogate%20endpoint%20(SE).

[Dr Bala]

The first sentence is really golden. No need to read the rest of the post because the post would entail zero scientific value.

[SkyLimit2022]

brazen22,

Thanks for reposting your ideas again, but you are misinformed. Seek credible full-context sources, including published peer-reviewed literature and licensed oncologists.

PFS is an intermediate endpoint that can only predict the hard endpoint of OS.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172692156